Apellis Slashes Costs To Focus On Troubled Syfovre Launch

Cuts To Jobs And Pipeline

The blockbuster-tipped eye therapy Syfovre has hit safety doubts and Apellis is streamlining to give more support to the drug’s global launch.

Apellis Pharmaceuticals has slashed its headcount by a quarter and culled its pipeline to save $300m, which will be put towards supporting the ongoing launch of its potential blockbuster eye therapy, Syfovre.

Syfovre (pegcetacoplan injection) became the first ever US Food and Drug Administration approved treatment for geographic atrophy (GA) in February

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

13 May 2025

• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

12 May 2025

• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Trump’s MFN Executive Order More Rhetoric Than Action

12 May 2025

• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.